

Inspectie Gezondheidszorg en Jeugd - Farmaceutische Producten

CERTIFICATE NUMBER: **NL/H 20/2017457**

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER^{1, 2}

Part 1

Issued following an inspection in accordance with :

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Netherlands confirms the following:

The manufacturer: ***SUN Pharmaceutical Industries Ltd. India, Halol***

Site address: ***Halol-Baroda Highway, Halol, Dist: Panchmahal,, Gujarat, 389350, India***

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 19(3) of Regulation 726/2004/EC .

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2020-02-07** , it is considered that it complies with :

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC³

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

¹ The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

² Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³ These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products	
1 MANUFACTURING OPERATIONS	
1.1	Sterile products
	<i>1.1.1 Aseptically prepared (processing operations for the following dosage forms)</i> 1.1.1.2 Lyophilisates 1.1.1.4 Small volume liquids
	<i>1.1.2 Terminally Sterilised (processing operations for the following dosage forms)</i> 1.1.2.1 Large volume liquids 1.1.2.3 Small volume liquids
1.2	Non-sterile products
	<i>1.2.1 Non-sterile products (processing operations for the following dosage forms)</i> 1.2.1.1 Capsules, hard shell 1.2.1.13 Tablets 1.2.1.17 Other: Inhalation powder, pre-dispensed(en)
1.5	Packaging
	<i>1.5.1 Primary Packaging</i> 1.5.1.1 Capsules, hard shell 1.5.1.13 Tablets 1.5.1.17 Other non-sterile medicinal products: Inhalation powder, pre-dispensed(en)
	<i>1.5.2 Secondary packaging</i>
1.6	Quality control testing
	1.6.1 Microbiological: sterility 1.6.2 Microbiological: non-sterility 1.6.3 Chemical/Physical

Any restrictions related to the scope of this certificate :

Building	Room	Line/equipment	QC testing	Products
Block A <i>(general non-sterile)</i>		General solid oral; Inhalation powder, pre-dispensed		
Block A1 <i>(hormones non-sterile)</i>		Hormone solid oral		
Block A2 <i>(cytotoxics sterile)</i>		PD-01		
Block A2 <i>(cytotoxics non-sterile)</i>		Cyto solid oral		
Block B <i>(general sterile)</i>		PMA-064, PMA-084, PMA-90, PMA-094, PMA-095, PMA-096		
Block D <i>(cytotoxics sterile)</i>		ANA-100, ANA-108		
Block E <i>(general sterile)</i>		PMB-105, PMB-166		
Block F <i>(packaging)</i>				
Block I <i>second floor (packaging hormones)</i>		Line 1		

2020-06-18

Name and signature of the authorised person of the
Competent Authority of Netherlands

Confidential
Health and Youth Care Inspectorate – Pharmaceutical
Products
Tel: ***Confidential***
Fax: ***Confidential***